Prostate Biopsy Specimen Analysis
Customize your policy alerts
Sign up for Blue Cross Blue Shield - Illinois Policy CPCPLABOOS alerts
Get alerted when Policy CPCPLABOOS changes without checking for updates manually.
Monitor payer policy activity
Defines plan reimbursement and specimen-handling criteria for pathological examination of prostate biopsy specimens for Blue Cross Blue Shield of Illinois members, affecting providers who submit claims for prostate biopsy pathology.
New policy establishing reimbursement criteria and specimen labeling guidance for prostate biopsy specimen analysis.
Coverage and Medical Necessity Criteria
Reimbursable Prostate Biopsy Pathology
Covered when ALL of the following clinical situations are met:
See Note 1 for specimen packaging/labeling
Saturation biopsy pathology is not reimbursable
Pathological examination of tissue obtained from a prostate saturation biopsy is explicitly excluded from reimbursement under this policy. The policy states that tissue from a prostate saturation biopsy "are not reimbursable for the diagnosis, staging and management of prostate cancer," and such claims may be denied when submitted for reimbursement.
Saturation biopsy pathology is considered not medically necessary per this policy and therefore will not be reimbursed. The document specifically indicates that pathological examination of tissue obtained from a prostate saturation biopsy is not reimbursable for diagnosis, staging, or management of prostate cancer.
Procedure and Billing Codes
| No codes listed |
| No codes listed |
| No codes listed |
| No codes listed |
Provider Responsibilities and Billing Actions
Check product coverage
Not all lab management reimbursement requirements apply to every product. Providers must review plan documents and the member's coverage to determine whether the lab reimbursement rules in this policy apply for the product and member being served.
- Review member plan documents (e.g., Certificates of Health Care Benefits, benefit booklets, Summary Plan Descriptions) to confirm coverage and applicable lab management reimbursement requirements.
Step therapy
No step therapy requirements are specified in this policy.
Required documentation
Providers are responsible for submission of accurate documentation of services performed. Submit complete clinical documentation supporting the medical necessity of the biopsy and pathology services, and ensure claims are coded using valid HIPAA-approved code sets (CPT, HCPCS, ICD-10, etc.) following industry-standard guidance.
- Include pathology reports and operative/procedure notes that document indication for biopsy (e.g., abnormal PSA, palpable nodule, suspicious imaging).
- Indicate whether biopsy was initial or follow-up and specify type (e.g., 12-core extended sampling).
- On request, submit additional documentation to support coverage and coding.
Specimen labeling and packaging
Specimen labeling and packaging must follow the plan's specimen guidance. For prostate biopsy reimbursement, specimens should be labeled and submitted consistent with billing conventions: one vial per sextant with no more than two core samples per vial. Each vial, regardless of number of cores, is considered a single specimen for billing.
- Improper specimen labeling or packaging (e.g., deviating from one vial per sextant / >2 cores per vial) may lead to claim denials.
- Pathology for prostate saturation biopsy is not reimbursable; billing for saturation biopsy pathology may trigger denial.
- Follow specimen labeling guidance to avoid denial triggers related to missing or incorrect specimen identification.
Background and Clinical Context
Pathological examination of prostate biopsy specimens is used both for initial diagnosis and for follow-up when clinical suspicion persists. Under this policy, pathological analysis of tissue from an extended 12-core prostate biopsy may be reimbursable when performed as part of the initial diagnostic workup following an abnormal PSA, a palpable nodule on digital rectal exam, or suspicious imaging. For follow-up biopsies after an initially negative result, pathology of repeat biopsies may be reimbursable except when the tissue originates from a prostate saturation biopsy, which is excluded. The policy also provides specimen-handling guidance for reimbursable biopsies: one vial per sextant with no more than two cores per vial, and each vial is billed as a single specimen.
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.